Adiponectin levels in nonalcoholic fatty liver disease

Metabolism: Clinical and Experimental

Volumn 60, Issue 12, 2011, Pages

  Abenavoli, Ludovico ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; METFORMIN;

BODY FAT; BODY MASS; DIET THERAPY; DRUG EFFICACY; GLUCOSE TOLERANCE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; LIVER FUNCTION; LOW DRUG DOSE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

FATTY LIVER; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MALE; METFORMIN;

EID: 81155155701     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2011.08.002     Document Type: Letter

References (3)

1. E. Sofer, M. Boaz, and Z. Matas Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial Metabolism 2011 10.1016/j.metabol.2011.01.011
2. A. Baranova, S.J. Gowder, and K. Schlauch Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance Obes Surg 16 2006 1118 1125 (Pubitemid 44433145)
3. G.A. Garinis, B. Fruci, and A. Mazza Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study Int J Obes (Lond) 34 2010 1255 1264